Portola Reports Q4 EPS -$0.82 Vs Est -$0.90, Announce Positive Phase 3 ANNEXA-R Study
March 02, 2015 at 08:05 AM EST
The randomized, double-blind, placebo-controlled Phase 3 ANNEXA-R study is evaluating the safety and efficacy of andexanet alfa in ...
